Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc (ADAP) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
adap · stock forecast · 16 analysts (3M) · FMP · updated Feb 12, 2026
Analyst Rating & Consensus
Based on 16 Wall Street analysts in the past 3 months
Buy
16 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$4.00
Consensus
$2.83
+7269.8% upside
Low
$1.00
Median: $3 · Last Close: $0.04
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.04 | ↓ 0.05% |
1-day model range: $0.04–$0.04. Peak: $0.04 (-0.05%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · ADAP · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|
Wall Street analysts have recently issued updated ratings on Adaptimmune Therapeutics plc (ADAP) stock. Of the recent 0 rating actions, 0 were upgrades and 0 were downgrades. 16 analysts currently cover ADAP.
Analyst Recommendation Trends
ADAP analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$27M
↓ 76.4% YoY
Revenue Next Year
$21M
↓ 24.6% YoY
EPS This Year
$-0.08
EPS Next Year
$-0.19
↑ 136.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast ADAP EPS of $-0.08 for the current fiscal year, based on estimates from 1 analysts. The ADAP revenue forecast is $27M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ADAP stock forecast is supported by two independent data sources: analyst consensus ratings from 16 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ADAP price target is $2.83 (+7269.8% upside), with an analyst consensus of Buy.
The ADAP short-term stock prediction for tomorrow is $0.04 (-0.05%).
Adaptimmune Therapeutics plc trades on NASDAQ under the ticker ADAP. The ADAP stock outlook for 2027 is broadly positive, supported by a Buy consensus among 56% of covering analysts.
Frequently asked questions
ADAP forecast · 8 questionsAccording to 16 Wall Street analysts, the average 12-month ADAP price target is $2.83, with a high forecast of $4.00 and a low of $1.00. The median price target is shown in the chart above when available. This implies +7269.8% potential upside from the current price of $0.04.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.